Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer and Merck Sharp and Dohme announce cancer collaboration

Pfizer and Merck Sharp and Dohme announce cancer collaboration

27th August 2014

Pfizer has announced a new partnership with Merck Sharp and Dohme on the development of a combination cancer therapy.

The companies aim to explore the therapeutic potential of a combination of Pfizer's crizotinib and Merck's investigational anti-PD-1 antibody pembrolizumab among patients with ALK-positive advanced or metastatic non-small cell lung cancer.

A phase Ib clinical study evaluating the safety and tolerability of the combination will be launched in 2015, with Pfizer taking the lead on this project.

Additional studies will also be conducted assessing pembrolizumab in combination with Pfizer's small molecule kinase inhibitor axitinib in patients with renal cell carcinoma, as well as a regime of pembrolizumab plus PF-05082566 for multiple cancer types.

Dr Mace Rothenberg, senior vice-president of clinical development and medical affairs and chief medical officer for Pfizer Oncology, said: "This collaboration between Pfizer and Merck is just one example of the willingness of sponsors to work together in an effort to accelerate progress against some of the most difficult-to-treat cancers."

This comes after the firm expanded its business capabilities through the acquisition of Baxter International's portfolio of marketed vaccines last month.ADNFCR-8000103-ID-801744648-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.